OPGx-BEST1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for OPGx-BEST1, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) [Phase 1, Phase 2]